Unexpectedly, this effect occurred downstream or independently of complex formation with BAK1 and associated downstream phosphorylation. RLK (LRR-RLK) BAK1/SERK3 is usually a prime candidate for any tradeoff mediator. BAK1 interacts with and is a positive regulator of the growth hormone brassinosteroid (BR) receptor, the LRR-RLK BRI1 (4,5). BRI1 can also complex with SERK1 and BKK1/SERK4 that play partially redundant functions with BAK1 in BR responses (68). BRI1 interacts with the inhibitory protein BKI1 that is displaced following BRI1 activation, followed by recruitment of BAK1 into the BRI1 complex (9). This prospects to further BRI1 activation and phosphorylation of cytoplasmic BSKs ultimately culminating at the transcription factors BZR1 and BES1/BZR2 (10). In innate immunity, BAK1 is usually a positive regulator forming a rapid ligand-induced complex with the LRR-RLKs FLS2 (11,12) and EFR (13), the pattern-recognition receptors (PRRs) perceiving the bacterial pathogen-associated molecular patterns (PAMPs) flagellin (flg22) and EF-Tu (elf18), respectively. Additional SERKs can be recruited by FLS2 with BKK1 as major regulator besides BAK1 (13). BAK1 also positively regulates other PRR-dependent pathways (12,1416). However, innate immune responses brought on by PAMPs such as fungal chitin do not depend on BAK1 (14,17). Together with BKK1, BAK1 also EC-17 disodium salt controls cell death (7,18). Signaling downstream of BAK1 differs between BRI1 and FLS2 pathways. BIK1 is bound to FLS2 and dissociates in a BAK1-dependent manner upon flg22 binding. BIK1 and paralogues positively regulate most PAMP-triggered immunity (PTI) responses EC-17 disodium salt downstream of FLS2 (19,20). FLS2 is usually ubiquitinated by the BAK1-associated ubiquitin ligases PUB12 and PUB13 and degraded (21). FLS2 activation prospects to quick bursts of calcium and reactive EC-17 disodium salt oxygen species (ROS), activation of MAP kinases and calcium-dependent protein kinases (CDPKs), ultimately leading to PTI (22). Upon BR binding, BRI1 auto- and transphosphorylates BAK1, leading to increased BAK1 autophosphorylation, which in turn transphosphorylates BRI1, resulting in optimal BRI1 activation (23). Activation of FLS2 or EFR by their corresponding ligand also prospects to phosphorylation of the ligand-binding RLKs and BAK1. BAK1 can provide signaling specificity in a phosphorylation-dependent manner (24). Thus, BAK1 may be a rate-limiting positive regulator, acting as a decision node between different pathways. BRI1 signaling output can be enhanced by over-expression or hyperactive alleles of BRI1 or positive regulators (8,2528), genetic or chemical inactivation of unfavorable regulators (9,29), or exogenous application of BR (30). This study addresses Vapreotide Acetate the hypotheses that BAK1 may cross-regulate or is usually rate-limiting in the BRI1 and FLS2/EFR pathways. We used primarily WTArabidopsisplants to reflect as faithfully as you possibly can the natural situation under which tradeoff between development and immunity may occur. == Results and Conversation == == Activation of BAK1 by BRs Does Not Lead to Immune Responses. == BRs have been implicated in tolerance to pathogens (3133). Therefore, we tested EC-17 disodium salt whether BRs induce responses associated with PTI. Based on the sequential phosphorylation model between BRI1 and BAK1 (23), activation of BAK1 EC-17 disodium salt by BRI1 could render the other receptor (i.e., FLS2) more active. An early PAMP response is the quick and transient production of ROS. To enable comparison between treatments and/or genotypes, the amount of ROS produced is usually plotted as the total amount of photons detected in the luminol-based assay during 40 min. Whereas treatment with the PAMPs flg22 and elf18 induced a clear ROS burst in WT.